Table 2. Summary of post hoc analysis of... | American Society of Hematology

Table 2.

Summary of post hoc analysis of prospective randomized studies

Study	DOAC	Anticoagulation indication	Obesity definition	Follow‐up duration, y	n, obesity/N, total population	Efficacy outcome			Safety outcome
Study	DOAC	Anticoagulation indication	Obesity definition	Follow‐up duration, y	n, obesity/N, total population	DOAC	VKA	P and/or HR (95% CI)	DOAC	VKA	P and/or HR (95% CI)
RE-LY³⁶	Dabigatran	AF	BMI >36 kg/m²	1	1811/18113 (10%)	0.9%^*	1.3%	P = .6	4.4%*	3.7%	P = .55
RE-LY³⁶	Dabigatran	AF	BMI >36 kg/m²	1	1811/18113 (10%)	1.2%†	1.3%	P = .6	3%†	3.7%	P = .55
ARISTOTLE³⁵	Apixaban	AF	Weight >120 kg	1	982/18139 (5.4%)	0.44%	1.13%	0.39 (0.12-1.22)	1.55%	2.08%	0.74 (0.37-1.50)
ENGAGE-AF TIMI 48²⁵	Edoxaban	AF	BMI ≥40 kg/m²	2.8 (median)	1149/21028 (5.5%)	2.2%§	1.4%§	1.37 (0.37-5.05)§	6.7%§	8.2%§	0.92 (0.54-1.57)§
ENGAGE-AF TIMI 48²⁵	Edoxaban	AF	BMI ≥40 kg/m²	2.8 (median)	1149/21028 (5.5%)	3.2%ǁ	1.4%ǁ	2.01 (0.58-6.97)ǁ	4.1%ǁ	8.2%ǁ	0.47 (0.26-0.85)ǁ
EINSTEIN³⁴ (DVT/PE)	Rivaroxaban	VTE	Weight ≥100 kg	1	1393/8271 (16.8%)	2.3%	2.0%	1.12 (0.55-2.30) P = .25	0.9%	1.2%	0.76 (0.26-2.19) P =.70
EINSTEIN³⁴ (DVT/PE)	Rivaroxaban	VTE	Weight ≥120 kg	1	303/8271 (3.7%)	1.9%	2.8%	N/A	N/A	NA	N/A

Study	DOAC	Anticoagulation indication	Obesity definition	Follow‐up duration, y	n, obesity/N, total population	Efficacy outcome			Safety outcome
Study	DOAC	Anticoagulation indication	Obesity definition	Follow‐up duration, y	n, obesity/N, total population	DOAC	VKA	P and/or HR (95% CI)	DOAC	VKA	P and/or HR (95% CI)
RE-LY³⁶	Dabigatran	AF	BMI >36 kg/m²	1	1811/18113 (10%)	0.9%^*	1.3%	P = .6	4.4%*	3.7%	P = .55
RE-LY³⁶	Dabigatran	AF	BMI >36 kg/m²	1	1811/18113 (10%)	1.2%†	1.3%	P = .6	3%†	3.7%	P = .55
ARISTOTLE³⁵	Apixaban	AF	Weight >120 kg	1	982/18139 (5.4%)	0.44%	1.13%	0.39 (0.12-1.22)	1.55%	2.08%	0.74 (0.37-1.50)
ENGAGE-AF TIMI 48²⁵	Edoxaban	AF	BMI ≥40 kg/m²	2.8 (median)	1149/21028 (5.5%)	2.2%§	1.4%§	1.37 (0.37-5.05)§	6.7%§	8.2%§	0.92 (0.54-1.57)§
ENGAGE-AF TIMI 48²⁵	Edoxaban	AF	BMI ≥40 kg/m²	2.8 (median)	1149/21028 (5.5%)	3.2%ǁ	1.4%ǁ	2.01 (0.58-6.97)ǁ	4.1%ǁ	8.2%ǁ	0.47 (0.26-0.85)ǁ
EINSTEIN³⁴ (DVT/PE)	Rivaroxaban	VTE	Weight ≥100 kg	1	1393/8271 (16.8%)	2.3%	2.0%	1.12 (0.55-2.30) P = .25	0.9%	1.2%	0.76 (0.26-2.19) P =.70
EINSTEIN³⁴ (DVT/PE)	Rivaroxaban	VTE	Weight ≥120 kg	1	303/8271 (3.7%)	1.9%	2.8%	N/A	N/A	NA	N/A

HR, hazard ratio. See Table 1 for expansion of other abbreviations.

Dabigatran 150 mg twice daily.

Dabigatran 110 mg twice daily.

Edoxaban 60 mg daily.

Edoxaban 30 mg daily.